Chemomab Therapeutics to Attend Upcoming Scientific Conferences

TEL AVIV, Israel, May 17, 2024 – Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a biotechnology firm at the clinical stage focusing on therapeutics for fibro-inflammatory diseases, has announced its participation in two significant scientific conferences. The company will present its latest research findings at the Gordon Research Conference on Chemotactic Cytokines and the EASL 2024, the Annual Congress of the European Association for the Study of the Liver.

Chemomab's presentations will discuss various subjects, including new preclinical studies that further explore the role of the soluble protein target CCL24 and the company's CCL24 neutralizing antibody, CM-101, in fibro-inflammatory diseases. Additionally, some presentations will delve into novel translational research that underpins the ongoing clinical development of CM-101 for primary sclerosing cholangitis, a rare and often fatal fibrotic liver condition. Detailed descriptions of the presentations will be available after the embargo is lifted.

At the Gordon Research Conference on Chemotactic Cytokines taking place in Portland, Maine from June 2-7, 2024, Prof. Amnon Peled from Hadassah University Hospital and the Faculty of Medicine at Hebrew University will deliver a poster presentation. The presentation, titled “Attenuating liver fibrosis and inflammation: blocking CCL24 inhibits recruitment of hepatic stellate cells, monocytes and neutrophils and modulates hepatic stellate cell activation,” will highlight crucial findings from their research.

During EASL Congress 2024 in Milan, Italy, from June 5-8, Chemomab will make several poster presentations. On June 6, from 8:30 to 18:00 CEST, Revital Aricha, PhD, Vice President of Translational Science at Chemomab Therapeutics, will present a poster on "Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101" in the Fibrosis/Stellate cell biology session, Abstract #380.

Also on June 6, from 8:30 to 17:00 CEST, Ilan Vaknin, PhD, Vice President of R&D at Chemomab Therapeutics, will present another poster titled "Machine learning-driven identification of serum protein signature for primary sclerosing cholangitis and enhanced liver fibrosis score" in the Immune-mediated and cholestatic: Experimental and pathophysiology session, Abstract #1032.

On June 7, from 12:25 to 13:45 CEST, Ilan Vaknin will again present the previously mentioned poster on "Ex-vivo translational assay of hepatic stellate cells using patient-derived serum characterizes the anti-fibrotic activity of CM-101" during the Fibrosis/Stellate Cell Biology Poster Tour, Abstract #380, at the Basic Science Track Hub.

Additionally, Chemomab Corporate Development will be present at the BIO International Convention's One-on-One Partnering event in San Diego from June 3-6, 2024. This platform allows registered attendees to schedule meetings with Chemomab representatives, providing an opportunity to discuss potential collaborations and partnerships within the industry.

Chemomab Therapeutics Ltd. is dedicated to developing innovative therapies for fibro-inflammatory diseases, which target the CCL24 protein known for playing a significant role in promoting fibrosis and inflammation. Their leading drug candidate, CM-101, is a monoclonal antibody designed to neutralize CCL24 activity. The company has shown positive results from three clinical trials, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in severe lung injury patients. Further, a Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with results expected mid-year 2024. The CM-101 program is also Phase 2-ready for the treatment of systemic sclerosis, supported by an open U.S. IND.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!